Christensenella is a Gram-negative, non-spore-forming, anaerobic, and nonmotile genus from the family Christensenellaceae. Christensenella minuta, Christensenella timonensis, and Christensenella massiliensis are currently the only known species of Christensenella, all of which were isolated from human stool samples. Development of therapeutic applications for Christensenella is an area of active research. Bacteria of the Christensenellaceae family hold great potential for therapeutic use as live biotherapeutic products to treat obesity and associated metabolic disorders. The larger role of Christensenella in the gut microbiome has also been a focal point for understanding how it may relate to other diseases.
Alternative Names
Christensenella minuta
FAQsPublished Data Customer Reviews Related Products
What are the recommended procedures for preparing Christensenella minuta for laboratory experiments?
Preparation involves reconstituting the lyophilized powder in an anaerobic environment to prevent exposure to oxygen, which could harm the bacteria. This step is essential to preserve the integrity and functionality of the bacteria before any experimental application.
How can the viability of Christensenella minuta be assessed before use?
Viability can be confirmed through various methods such as viability assays, which include plating on selective media and checking for colony formation. These methods help ensure that the bacteria are active and capable of exhibiting desired effects in studies.
What are the best practices for administering Christensenella minuta in animal models?
Administration should be done carefully to ensure that the dosage and method align with the study's design. Typically, it is administered orally in animal models to study its effects on the gut microbiome and metabolic health. Ensuring accurate dosing is key to obtaining reliable and reproducible results.
What are the disposal guidelines for Christensenella minuta after experimentation?
Post-experimentation, it is important to dispose of Christensenella minuta cultures and any associated waste properly to prevent environmental contamination. This typically involves autoclaving cultures before disposal, following biosafety guidelines.
What future research directions are suggested for Christensenella minuta?
Future research is encouraged to explore the detailed mechanisms by which Christensenella minuta influences metabolic health and interacts with host tissues. Understanding these interactions could lead to novel therapeutic strategies for treating obesity and related metabolic diseases .
C. minuta 33407 modulated the fecal microbiome in a DIO mouse model assessed after 40 days of oral treatment (min n = 8)
The study explored the anti-obesity potential of a novel strain of Christensenella minuta 33407 in preclinical models. The research used a diet-induced obesity (DIO) mouse model and a humanized model to assess the effects of this strain on metabolic health. In the DIO mouse model, mice treated with C. minuta 33407 exhibited significant reductions in body weight gain, fat mass accumulation, and mesenteric white adipose tissue hypertrophy compared to the control group. The treatment also improved feed efficiency and reduced circulating levels of leptin and resistin, indicating a healthier metabolic profile. Additionally, hepatic triglyceride and free fatty acid levels were significantly lower in the treated group, suggesting a regulatory effect on hepatic lipid metabolism. The strain also modulated gut microbiota composition, increasing microbial diversity and restoring the Firmicutes/Bacteroidetes ratio. In the model, C. minuta 33407 treatment increased short-chain fatty acid production and reduced branched-chain fatty acid levels, further supporting its role in improving gut health. These findings highlight the therapeutic potential of C. minuta 33407 in managing obesity and associated metabolic disorders.
Mazier, W., Le Corf, K., et al. A new strain of Christensenella minuta as a potential biotherapy for obesity and associated metabolic diseases. Cells. 2021, 10(4): 823. Distributed under Open Access license CC BY 4.0, without modification.
Unmatched Purity and Viability
Creative Biolabs' Christensenella minuta offers unparalleled purity and viability, essential for consistent results in metabolic health research.
Advanced Genetic Stability
Creative Biolabs ensures exceptional genetic stability in their Christensenella minuta, making it a reliable choice for long-term studies.
Reliable Anaerobic Packaging
The anaerobic packaging of Christensenella minuta ensures that we receive the product in optimal condition every time, ready for immediate use in our lab.
Creative Biolabs' Precision Dosing
With precision dosing instructions provided by Creative Biolabs, we can administer the exact amount needed for our metabolic syndrome studies, ensuring consistent results.
Efficient Customer Support
The customer support team at Creative Biolabs is always ready to assist with any inquiries regarding the proper use of Christensenella minuta, greatly enhancing our research efficiency.
Click the button below to contact us or submit your feedback about this product.
